Double Relapsed and/or Refractory Multiple Myeloma: Clinical Outcomes and Real World Healthcare Costs

Double relapsed and/or refractory multiple myeloma (DRMM), MM that is relapsed and/or refractory to bortezomib and lenalidomide, carries a poor prognosis. The healthcare costs of DRMM have not previously been reported. We analyzed detailed medical resource utilization (MRU) costs, drug costs and out...

Descripción completa

Detalles Bibliográficos
Autores principales: Gooding, Sarah, Lau, I-Jun, Sheikh, Mimi, Roberts, Pamela, Wong, Julia, Dickens, Emmy, Bullement, Ash, Elvidge, Jamie, Lee, Dawn, Ramasamy, Karthik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4569348/
https://www.ncbi.nlm.nih.gov/pubmed/26367874
http://dx.doi.org/10.1371/journal.pone.0136207
_version_ 1782390028078415872
author Gooding, Sarah
Lau, I-Jun
Sheikh, Mimi
Roberts, Pamela
Wong, Julia
Dickens, Emmy
Bullement, Ash
Elvidge, Jamie
Lee, Dawn
Ramasamy, Karthik
author_facet Gooding, Sarah
Lau, I-Jun
Sheikh, Mimi
Roberts, Pamela
Wong, Julia
Dickens, Emmy
Bullement, Ash
Elvidge, Jamie
Lee, Dawn
Ramasamy, Karthik
author_sort Gooding, Sarah
collection PubMed
description Double relapsed and/or refractory multiple myeloma (DRMM), MM that is relapsed and/or refractory to bortezomib and lenalidomide, carries a poor prognosis. The healthcare costs of DRMM have not previously been reported. We analyzed detailed medical resource utilization (MRU) costs, drug costs and outcomes for 39 UK patients receiving standard DRMM therapy. Median OS in this cohort was 5.6 months. The mean cost of DRMM treatment plus MRU until death was £23,472 [range: £1,411–£90,262], split between drug costs £11,191 and other resource use costs £12,281. The cost per assumed quality-adjusted life year (QALY) during DRMM was £66,983. These data provide a standard of care comparison when evaluating the cost-effectiveness of new drugs in DRMM.
format Online
Article
Text
id pubmed-4569348
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-45693482015-09-18 Double Relapsed and/or Refractory Multiple Myeloma: Clinical Outcomes and Real World Healthcare Costs Gooding, Sarah Lau, I-Jun Sheikh, Mimi Roberts, Pamela Wong, Julia Dickens, Emmy Bullement, Ash Elvidge, Jamie Lee, Dawn Ramasamy, Karthik PLoS One Research Article Double relapsed and/or refractory multiple myeloma (DRMM), MM that is relapsed and/or refractory to bortezomib and lenalidomide, carries a poor prognosis. The healthcare costs of DRMM have not previously been reported. We analyzed detailed medical resource utilization (MRU) costs, drug costs and outcomes for 39 UK patients receiving standard DRMM therapy. Median OS in this cohort was 5.6 months. The mean cost of DRMM treatment plus MRU until death was £23,472 [range: £1,411–£90,262], split between drug costs £11,191 and other resource use costs £12,281. The cost per assumed quality-adjusted life year (QALY) during DRMM was £66,983. These data provide a standard of care comparison when evaluating the cost-effectiveness of new drugs in DRMM. Public Library of Science 2015-09-14 /pmc/articles/PMC4569348/ /pubmed/26367874 http://dx.doi.org/10.1371/journal.pone.0136207 Text en © 2015 Gooding et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Gooding, Sarah
Lau, I-Jun
Sheikh, Mimi
Roberts, Pamela
Wong, Julia
Dickens, Emmy
Bullement, Ash
Elvidge, Jamie
Lee, Dawn
Ramasamy, Karthik
Double Relapsed and/or Refractory Multiple Myeloma: Clinical Outcomes and Real World Healthcare Costs
title Double Relapsed and/or Refractory Multiple Myeloma: Clinical Outcomes and Real World Healthcare Costs
title_full Double Relapsed and/or Refractory Multiple Myeloma: Clinical Outcomes and Real World Healthcare Costs
title_fullStr Double Relapsed and/or Refractory Multiple Myeloma: Clinical Outcomes and Real World Healthcare Costs
title_full_unstemmed Double Relapsed and/or Refractory Multiple Myeloma: Clinical Outcomes and Real World Healthcare Costs
title_short Double Relapsed and/or Refractory Multiple Myeloma: Clinical Outcomes and Real World Healthcare Costs
title_sort double relapsed and/or refractory multiple myeloma: clinical outcomes and real world healthcare costs
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4569348/
https://www.ncbi.nlm.nih.gov/pubmed/26367874
http://dx.doi.org/10.1371/journal.pone.0136207
work_keys_str_mv AT goodingsarah doublerelapsedandorrefractorymultiplemyelomaclinicaloutcomesandrealworldhealthcarecosts
AT lauijun doublerelapsedandorrefractorymultiplemyelomaclinicaloutcomesandrealworldhealthcarecosts
AT sheikhmimi doublerelapsedandorrefractorymultiplemyelomaclinicaloutcomesandrealworldhealthcarecosts
AT robertspamela doublerelapsedandorrefractorymultiplemyelomaclinicaloutcomesandrealworldhealthcarecosts
AT wongjulia doublerelapsedandorrefractorymultiplemyelomaclinicaloutcomesandrealworldhealthcarecosts
AT dickensemmy doublerelapsedandorrefractorymultiplemyelomaclinicaloutcomesandrealworldhealthcarecosts
AT bullementash doublerelapsedandorrefractorymultiplemyelomaclinicaloutcomesandrealworldhealthcarecosts
AT elvidgejamie doublerelapsedandorrefractorymultiplemyelomaclinicaloutcomesandrealworldhealthcarecosts
AT leedawn doublerelapsedandorrefractorymultiplemyelomaclinicaloutcomesandrealworldhealthcarecosts
AT ramasamykarthik doublerelapsedandorrefractorymultiplemyelomaclinicaloutcomesandrealworldhealthcarecosts

Ejemplares similares